论文部分内容阅读
目的:探讨利妥昔单抗治疗乙型肝炎病毒相关性膜性肾病(HBV-MN)的有效性和安全性.方法:通过1例HBV-MN患者的免疫抑制治疗,结合最新指南和文献,总结HBV-MN的治疗现状,分析利妥昔单抗用于HBV-MN治疗的前景.结果:HBV-MN治疗无统一方案,尚无利妥昔单抗用于HBV-MN治疗的文献报道.本例HBV-MN患者应用利妥昔单抗进行免疫抑制治疗,疗效显著,安全性高.结论:利妥昔单抗应用于HBV-MN治疗的有效性和安全性,以及具体治疗方案和监测指标的制定均有待进一步研究.“,”Objective:To investigate the efficacy and safety of rituximab in the treatment of hepatitis B virus-associated membranous nephropathy (HBV-MN).Methods:The treatment of one patient with HBV-MN was analyzed.According to the latest guidelines and literature,the status of HBV-MN treatment was summarized,and the application prospect of rituximab in HBV-MN was analyzed.Results:There was neither uniform regimen of HBV-MN therapy,nor literature report of rituximab in the treatment of HBV-MN.For the case reported in this article,the efficacy and safety of rituximab in the treatment of HBV-MN was satisfying.Conclusion:The efficacy and safety of rituximab in the treatment of HBV-MN,the treatment regimen and monitoring indicators need to be further studied.